FECAL BEHENIC ACID MARKER

粪便山萮酸标记物

• 批准号: 7607763
• 负责人: JAMES E. HEUBI
• 金额: $ 6.63万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607763
• 关键词: Adult; Blood Coagulation Disorders; Celiac Disease; Clinical; Collection; Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis; Development; Diagnosis; Dietary Fats; Dietary History; Digestion; Disease; Dose; Equilibrium; Failure; Fat-Soluble Vitamin; Fatty Acids; Fatty acid glycerol esters; Feces; Funding; Gold; Grant; Growth; Hour; Inflammatory Bowel Diseases; Ingestion; Institution; Intake; Liver diseases; Malabsorption Syndromes; Malnutrition; Measures; Methods; Neurologic Deficit; Osteoporosis; Output; Pancreatic enzyme; Research; Research Personnel; Resources; Rickets; Sampling; Skin; Source; Spottings; Standards of Weights and Measures; Steatorrhea; Stress; Testing; Time; United States National Institutes of Health; Visual; Vitamin A; absorption; base; behenic acid; chronic pancreatitis; day

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Fat malabsorption (steatorrhea) results from impaired digestion or absorption of dietary fats and it can be caused by multiple diseases including cystic fibrosis, chronic pancreatitis, cholestatic liver disease, celiac disease, and inflammatory bowel disease. If untreated, fat malabsorption may result in malnutrition, growth failure, and deficiencies of fat-soluble vitamins A/E/D/K with resultant skin and visual changes, neurologic deficits, osteoporosis/rickets and coagulopathy. Currently the gold standard test to diagnose steatorrhea remains the fat balance study, which is based on the premise that fat intake minus fat output equals fat absorbed. This test is very time consuming as it requires a three to five day stool collection and complete dietary history. These limitations make this test impractical in the clinical setting and stress the need for a facile, accurate test of fat malabsorption. The development of a facile means to quantitative measure fat loss in the stool is urgently needed. Despite previous attempts to develop simpler methods than the 72 hour fecal fat collection method, none have proven to be easier and as reliable as the gold standard. In the current proposal, fat absorption will be measured by assessing stool behenic acid concentration in "spot stool" samples after giving a standardized dose will predictable correlate with fat absorption assessed using the quantitative measure of fat absorption in the gold standard, the 72 hour fecal fat collection in healthy control adults. The ratio of behenic acid in a "spot sample" of stool after ingestion of a known quantity of this fatty acid compared to total fatty acids in stool will be measured and compared to the results of absorption using behenic acid as a marker compared to the "gold standard," the 72 hour fecal fat collection method when subjects are treated with pancreatic enzymes compared to a period when they are receiving no pancreatic enzyme supplements.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 脂肪吸收不良（脂肪泻）是由膳食脂肪的消化或吸收受损引起的，可由多种疾病引起，包括囊性纤维化、慢性胰腺炎、胆汁淤积性肝病、乳糜泻和炎症性肠病。 如果不加以治疗，脂肪吸收不良可能会导致营养不良、生长障碍和脂溶性维生素 A/E/D/K 缺乏，从而导致皮肤和视力变化、神经系统缺陷、骨质疏松症/佝偻病和凝血病。 目前诊断脂肪泻的金标准测试仍然是脂肪平衡研究，其前提是脂肪摄入量减去脂肪输出量等于脂肪吸收量。 该测试非常耗时，因为它需要三到五天的粪便收集和完整的饮食史。 这些限制使得该测试在临床环境中不切实际，并且强调需要对脂肪吸收不良进行简便、准确的测试。迫切需要开发一种简便的方法来定量测量粪便中的脂肪损失。尽管之前曾尝试开发比 72 小时粪便脂肪收集方法更简单的方法，但没有一个方法被证明比金标准更简单、更可靠。在目前的提案中，将通过在给予标准化剂量后评估“现场粪便”样本中的粪便山萮酸浓度来测量脂肪吸收，这将与使用金标准（72小时粪便）中脂肪吸收的定量测量方法评估的脂肪吸收相关。健康对照成人的脂肪收集。将测量摄入已知量的这种脂肪酸后粪便“点样”中山萮酸与粪便中总脂肪酸的比率，并将其与使用山萮酸作为标记物的吸收结果进行比较。黄金标准”，即受试者接受胰酶治疗时与未接受胰酶补充剂的时期相比的 72 小时粪便脂肪收集方法。